Viewing Study NCT04949256


Ignite Creation Date: 2025-12-24 @ 11:35 PM
Ignite Modification Date: 2026-01-01 @ 6:42 PM
Study NCT ID: NCT04949256
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-15
First Post: 2021-06-29
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module